<DOC>
	<DOCNO>NCT01789788</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , multiple ascend dose study evaluate safety , tolerability , pharmacokinetics pharmacodynamics RO6811135 patient type 2 diabetes mellitus . Patients randomize receive either RO6811135 placebo daily 2 week , follow-up examination 2 3 week last dose study drug .</brief_summary>
	<brief_title>A Safety , Pharmacokinetics Pharmacodynamics Study RO6811135 Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Adult patient , 18 65 year age , inclusive Type 2 diabetes mellitus accord WHO criteria diagnose least 3 month prior screen On stable dose metformin least 2 month prior screen Fasting plasma glucose screening period &lt; /= 240 mg/dL Hemoglobin A1c ( HbA1c ) level screen &gt; /= 6.5 % &lt; /= 10.5 % Evidence insulin secretory capacity screen Body mass index ( BMI ) 27 42 kg/m2 , inclusive Females childbearing potential male female partner childbearing potential must agree use effective contraception define protocol Type 1 diabetes Acquired secondary form diabetes result pancreatic surgery/injury , cystic fibrosis relate diabetes History acute metabolic complication diabetic ketoacidosis state hyperosmolar hyperglycemia Evidence history clinically significant diabetic complication clinically severe diabetic peripheral neuropathy , clinically significant nephropathy judge investigator , preproliferative/proliferative diabetic retinopathy judge investigator History severe symptomatic hypoglycemia ( require assistance third party ) within 6 month prior screen History presence clinically significant concomitant disease disorder Hemoglobin level lower limit reference range screen Pregnant lactate woman History anaphylaxis severe systemic hypersensitivity allergic reaction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>